Pharma Two B raises $30M for Parkinson’s phase 3 from Biogen-backed fund, adds ex-Pfizer CEO to board
by Nick Paul Taylor | Feb 27, 2017 7:34am Pharma Two B will run a phase 3 of its pramipexole-rasagiline fixed-dose combination P2B001. Pharma Two B has raised $30 million (€28 million) to complete a phase 3 trial of its Parkinson’s asset P2B001. The round provides a hint of the impact of the recently founded [...]